Mankind Pharma Q4 Results: Net profits jumped 52%, revenues up 19%
Newly listed healthcare products manufacturer Mankind Pharma recently reported its results for the March quarter. The company witnessed sharp growth in both revenue and profits from the previous year.
Notably, Mankind’s popular and trusted brands along with a leading market share in the categories can be attributed as the factors that led to this growth.
Since its listing, the Mankind Pharma share price has had a tough ride. Highlighted with a raid on its premises by the Income Tax Department, the share price has had a turbulent ride so far, falling close to 3.5%.
So, how much revenue did Mankind Pharma clock? Did the Mankind Pharma margins improve from the prior year? What were the net profits reported by Mankind Pharma? Did Mankind Pharma declare any dividend? Let’s try and decode!
Decoding Mankind Pharma earnings
Mankind Pharma revenues:
- Mankind Pharma’s revenue from operations for the March quarter came in at Rs 2,053 crores. This denotes a growth of 19% from the previous year. Notably, in the year-ago period, the company’s revenues came in at Rs 1,726 crores.
- The revenues from the core Domestic business witnessed a growth of 18% from the previous year to Rs 1,972 crores in the Jan - Mar ‘23 period. Notably, the segment contributed 97% to the company’s total revenues.
- Moreover, revenues from the Exports business jumped by 63% yearly to stand at Rs 81 crores for the March quarter.
Mankind Pharma margins: Operating profit margins for the March quarter stood at 20.4%. This marked an improvement from the previous year’s figure of 16.8%.
Moreover, operating profits jumped by 45% from the prior year to Rs 419 crores for the Jan - Mar ‘23 period.
Mankind Pharma dividend: Mankind Pharma did not declare any dividend during the quarter.
Mankind Pharma net profits: Net profits for the Jan - Mar ‘23 period came in at Rs 294 crores. This marked a growth of 52% from the previous year.
In the year-ago period, the company’s net profits stood at Rs 193 crores.
Mankind Pharma earnings: Analyst target price
Macquarie: The renowned brokerage has a “Buy” rating on the stock with a price target of Rs 1,400.
What were Mankind Pharma revenues in Q4FY23?
Mankind Pharma’s revenue from operations for the March quarter came in at Rs 2,053 crores. This denotes a growth of 19% from the previous year.
What were Mankind Pharma net profits in Q4FY23?
Net profits for the Jan - Mar ‘23 period came in at Rs 294 crores. This marked a growth of 52% from the previous year.
What was the Mankind Pharma dividend?
Mankind Pharma did not declare any dividend during the quarter.